Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CHKA | P35790 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20443001 | 0.89 | ALDH1A1 (0.54) | HRH3CYP1A2CYP2D6KDM4ENPC1 | |
| SCHEMBL19291968 | 0.88 | CHKA (0.59) | LMNAMC4RKDM4ECHKANPC1 | |
| SCHEMBL21414371 | 0.88 | HRH3 (0.52) | LMNAHRH3MC4RCYP1A2CYP2D6 | |
| SCHEMBL17409816 | 0.87 | HRH3 (0.59) | LMNAHRH3MC4RCYP1A2CYP2D6 | |
| SCHEMBL20356732 | 0.87 | HRH3 (0.62) | HRH3CYP1A2CYP2D6KDM4ENCF1 | |
| SCHEMBL21414363 | 0.86 | ALDH1A1 (0.55) | LMNAHRH3CYP1A2CYP2D6KDM4E | |
| SCHEMBL17645702 | 0.86 | LMNA (0.50) | LMNAHRH3MC4RKDM4ECHKA | |
| SCHEMBL25728960 | 0.85 | CYP1A2 (0.63) | HRH3CYP1A2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL12651283 | 0.83 | HRH3 (0.53) | LMNAHRH3CYP1A2CYP2D6NPC1 | |
| SCHEMBL21414343 | 0.83 | CXCR4 (0.49) | HRH3CYP1A2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| EP-3546458-B1 | ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER | TEIJIN PHARMA LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3546458-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | LMNA 3355/4885HRH3 387/4885MC4R 2492/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | LMNA 4411/4885HRH3 1501/4885MC4R 1384/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | LMNA 2388/4885HRH3 3157/4885MC4R 3561/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | LMNA 2831/4885HRH3 1610/4885MC4R 2968/4885 |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | LMNA 3711/4885HRH3 2223/4885MC4R 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.